Isoniazid monoresistance and alopecia occurred together in one TB case

What the study found: A 22-year-old woman with pulmonary tuberculosis developed sudden, severe hair loss after starting antituberculosis treatment. The authors report that isoniazid, a tuberculosis drug, was suspected as the cause and later drug testing showed isoniazid monoresistance.
Why the authors say this matters: The authors conclude that clinicians should be vigilant for alopecia, which means hair loss, in young female patients receiving antituberculosis treatment because it may lead to treatment interruption for cosmetic reasons. They also suggest that alopecia may signal underlying drug resistance, although they note that more studies are needed to establish biological evidence for this association.
What the researchers tested: The report describes a single case of pulmonary tuberculosis in a 22-year-old woman. After she developed hair loss one month after treatment began, isoniazid was stopped, drug resistance testing was performed, and treatment was adjusted.
What worked and what didn't: Hair regrowth was observed within one month after isoniazid was discontinued. Drug resistance testing revealed isoniazid monoresistance, and treatment was continued with rifampicin, pyrazinamide, ethambutol, and moxifloxacin for 2 months, followed by rifampicin and ethambutol for 7 months.
What to keep in mind: This is a single case report, so the findings are limited to one patient. The abstract does not describe broader rates, comparisons, or proven biological mechanisms linking alopecia and drug resistance.

Key points

• A 22-year-old woman with pulmonary tuberculosis developed sudden, severe hair loss after starting treatment.
• Isoniazid was suspected as the cause of the alopecia and was stopped.
• Drug resistance testing later showed isoniazid monoresistance.
• Hair regrowth was seen within one month after isoniazid discontinuation.
• The authors say alopecia may warrant attention in young female patients on antituberculosis treatment and may be associated with drug resistance.